Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lasmiditan in Acute Migraine (SPARTAN)
NCT02605174Phase 3Completed
- Sponsor
- Eli Lilly and Company
- Start
- May 2016
- Primary completion
- Jun 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of lasmiditan in migraine (4 arms), sponsored by Eli Lilly and Company. Primary endpoints: Percentage of Participants Headache Pain Free at 2 Hours Post Dose and Percentage of Participants Who Are Most Bothersome Symptom (MBS) Free at 2 hours. Started May 2016; status: completed.
02
Drugs
lasmiditan
03
Conditions
migraine
Beyond the preview
Go deeper on NCT02605174.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02605174.